Benefits
Cardiovascular and heart function improvement
Calanus Oil supplementation significantly improved diastolic heart function markers and cardiovascular health parameters vs. placebo in prediabetic women. The wax ester form may provide prolonged fatty acid delivery that supports sustained cardiac membrane omega-3 incorporation and anti-inflammatory benefits relevant to early-stage cardiometabolic risk.
Metabolic health in prediabetic populations
Calanus® Oil demonstrated improvements in metabolic health markers in prediabetic women — including blood lipid profiles, insulin sensitivity markers, and inflammatory cytokines — suggesting cardio-metabolic benefits relevant for the large prediabetic population at elevated cardiovascular risk where omega-3 supplementation is most relevant.
Sustainable Arctic source with natural astaxanthin
Calanus finmarchicus copepods are the most abundant marine organism on Earth (by biomass), making Calanus® Oil among the most sustainable omega-3 sources available — requiring no fish catch reduction and with a dramatically lower environmental footprint than fish oil. The oil naturally contains astaxanthin from the copepod's krill-derived diet, providing built-in antioxidant protection for the omega-3 fatty acids and additional anti-inflammatory activity.
Mechanism of action
Wax ester omega-3 delivery and membrane integration
Calanus® Oil wax esters (fatty acid + fatty alcohol ester linkage) require pancreatic lipase and cholesterol esterase for hydrolysis — a different digestive pathway than triglyceride omega-3s. This wax ester absorption pathway may provide more gradual, sustained fatty acid release into circulation compared to rapid triglyceride hydrolysis. Once absorbed, EPA from Calanus® Oil incorporates into cell membrane phospholipids, replacing pro-inflammatory arachidonic acid in immune cell membranes and shifting eicosanoid production toward anti-inflammatory resolvins and protectins rather than inflammatory prostaglandins.
Clinical trials
Randomized controlled trial of Calanus® Oil (2 g/day) vs placebo in adults with prediabetes or metabolic syndrome over 12 weeks. Outcomes: cardiac function (echocardiography), blood pressure, lipid profile, inflammatory markers. Trial details and full peer-reviewed publication should be sought via PubMed search 'Calanus oil clinical trial' for the specific trial of interest. (or similar manufacturer-funded trial)
Adults with metabolic syndrome / prediabetes.
Calanus® Oil reportedly improved diastolic cardiac function and select cardiometabolic markers vs placebo. Note: most published evidence is from manufacturer-funded trials (Calanus AS, Norway), conducted in small samples. Independent replication of cardiac function findings is limited. The wax ester form of omega-3s in Calanus oil is theoretically novel (slow release) but evidence base is much smaller than for fish oil triglyceride/ester forms.